Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claim ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Anika Therapeutics and its officers or directors [1] Group 1: Company Performance - On July 30, 2025, Anika announced topline results from its pivotal clinical trial of Hyalofast, which showed improvements in treated patients but did not meet pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID [3] - Following the announcement, Anika's stock price dropped by $3.06, or 27.42%, closing at $8.10 per share [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Anika for claims related to potential securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered multimillion-dollar damages for class members [4]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --  Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential clai ...

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether Anika and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On July 30, 2025, Anika issued a press release announcing topline results from its clinical trial of Hyalofast, “a reso ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 (781) 457-9000 (Registrant's Telephone Number, Including Area Code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in ...

Anika Therapeutics (ANIK) Q2 2025 Earnings Call July 30, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to Anika's Second Quarter Earnings Conference Call. I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations. Please proceed.Speaker1Thank you. Good morning, and thank youSpeaker2for joining us for Anika's second quarter '20 twenty five conference call and webcast. I'm Matt Hall, Anika's Director of Corporate Development and Investor Rela ...

Q2 2025 EARNINGS CALL JULY 30, 2025 Anika. Restore Active Living. SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within the meanin ...

EXHIBIT 99.1 Anika Reports Second Quarter 2025 Financial Results Regenerative Solutions revenue up 41% with Integrity Implant System ahead of expectations and continued strong Hyalofast growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other mea ...

Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second ha ...

Core Viewpoint - Anika Therapeutics, Inc. will release its second quarter 2025 financial results on July 30, 2025, followed by a conference call to discuss the results and business highlights [1]. Company Overview - Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care, leveraging expertise in hyaluronic acid and implant solutions [3]. - The company aims to provide minimally invasive products that enhance active living, particularly in high opportunity areas such as Osteoarthritis Pain Management and Regenerative Solutions [3]. - Anika's operations are headquartered outside of Boston, Massachusetts, and its products are delivered efficiently in key care sites, including ambulatory surgery centers [3]. Conference Call Details - The conference call to discuss the financial results can be accessed via a toll-free domestic number or an international number, with a conference ID provided [2]. - A live audio webcast and presentation materials will be available on Anika's Investor Relations website, and the call will be archived for later access [2].